Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) dropped 1.9% on Thursday . The stock traded as low as $6.76 and last traded at $6.78, with a volume of 118,686 shares trading hands. The stock had previously closed at $6.91.

Several equities analysts have recently commented on the company. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 19th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $11.00 target price on shares of Aratana Therapeutics in a report on Tuesday, March 22nd. William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a report on Tuesday, April 26th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $12.00 target price on shares of Aratana Therapeutics in a report on Saturday, April 2nd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $13.28.

The firm’s market capitalization is $240.01 million. The stock has a 50-day moving average of $6.66 and a 200 day moving average of $5.25.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.10. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.13 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The business’s revenue was up 6.3% on a year-over-year basis. Analysts anticipate that Aratana Therapeutics Inc. will post ($1.08) EPS for the current year.

In other news, insider Julia A. Stephanus sold 30,000 shares of Aratana Therapeutics stock in a transaction on Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total transaction of $187,500.00. Following the transaction, the insider now directly owns 127,503 shares of the company’s stock, valued at $796,893.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Peter Steven St sold 100,000 shares of Aratana Therapeutics stock in a transaction on Friday, June 17th. The stock was sold at an average price of $6.26, for a total transaction of $626,000.00. Following the transaction, the chief executive officer now directly owns 717,793 shares in the company, valued at $4,493,384.18. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Aratana Therapeutics stock. Jennison Associates boosted its position in Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned 11.84% of Aratana Therapeutics worth $35,077,000 at the end of the most recent reporting period.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.